Table 2.
Variable | T0 | 2s | 3s | 4s | 5s | 6s | 7s | 8s | 9s | T1 | T2 | T3 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
HAMD | X | X | X | |||||||||
FIQ | X | X | X | X | ||||||||
0-100 mm VAS | X | X | X | X | ||||||||
SF12 | X | X | X | X | ||||||||
Genogram | X | |||||||||||
Tender points count | X | X | X | X | ||||||||
Pain threshold | X | X | X | X | ||||||||
Improvement perceived by patient | X | |||||||||||
Expectations and credibility | X | X | ||||||||||
Side effects | X | |||||||||||
Diagnosis by traditional Chinese medicine | X | X | ||||||||||
Medication consumed | X | X | ||||||||||
Occupational data | X | X | X | X | ||||||||
Sociodemographic data | X |
VAS: Pain intensity measured on a visual analogue scale; HAMD: Hamilton scale; FIQ: Fibromyalgia Impact Questionnaire; T0: Baseline value; T1: Final value (10 weeks after start of treatment); T2: Follow-up evaluation 1 (6 months after start of treatment); T3: Follow-up evaluation 2 (12 months after start of treatment); #s: Session number.